Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3
AREDS2 Research Group, Chew EY, Clemons TE
Published in JAMA Ophthalmology
Key Findings
In participants with the lowest dietary lutein/zeaxanthin intake, supplementation reduced progression to advanced AMD; lutein/zeaxanthin was a safer substitute for beta-carotene.
Conclusions
Benefit concentrated in low-intake individuals.
Limitations
Secondary analysis of a factorial trial.
Supplements Studied
In secondary analyses, lutein/zeaxanthin was associated with reduced progression to advanced AMD compared with beta-carotene, particularly in participants with low dietary intake.
In participants with the lowest dietary intake, lutein/zeaxanthin supplementation reduced progression to advanced age-related macular degeneration.
In participants with the lowest dietary lutein/zeaxanthin intake, supplementation reduced progression to advanced AMD; lutein/zeaxanthin was a safer substitute for beta-carotene.
Outcomes Measured
Lutein/zeaxanthin reduced progression to advanced macular degeneration in low-intake participants.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.